CSL is paying $355M for a share in a Swiss antibody for failing kidneys, nearly as much as venture investors put into its maker over seven years. Alentis keeps 45 percent of the profit and no royalty. The contract that defines that profit is unpublished, and so are the licences

On 6 October Rocket Pharmaceuticals announced that Hercules Capital had lent it $35.0M, the first draw on a senior secured facility of up to $150.0M signed on 30 September. The press release said the money, with the cash already in hand, would fund the company into the third

On 28 September 2026 two announcements about crop genetics went out within hours of each other. Cibus, a gene-editing company listed on Nasdaq, said that Crystal Crop Protection of New Delhi would develop gene-edited traits in Brassica juncea, India's mustard, and "evaluate and commercialize such

On 9 February 2023 Richard Gonzalez, AbbVie's chief executive, told analysts to expect "U.S. Humira sales down approximately 37%" that year. Humira had lost its American exclusivity at the end of January, the moment the industry calls a patent cliff, and cheaper copies known as

CSL paid Alentis USD 355m upfront for 45 per cent of global profits on lixudebart, the largest licence payment of the week, and of the 12 royalties and profit shares created in the window two publish a rate, two publish a band and eight publish nothing. Shionogi agreed to pay

On 25 September 2026 the European Commission revoked the marketing authorisation for Aumseqa (aumolertinib), a lung-cancer drug developed by Hansoh Pharmaceutical of China. It had granted that authorisation on 12 February 2026, so the approval lasted 225 days. Hansoh reports no sales revenue outside China. The decision turned on

On 21 October a bankruptcy judge in Delaware is due to hear the sale of BioXcel Therapeutics, the maker of Igalmi. Teva has offered $57.5M in cash. The two lenders paying for the case, Oaktree Capital Management and Qatar Investment Authority, have committed up to $77.25M to it,

JCR has licensed its Hunter syndrome drug outside Japan for the second time in five years. It has now signed twelve out-licences since 2021 and has never published a royalty rate. A rival drug built the same way has one: 9.25 percent, bought by Royalty Pharma.

On 9 January 2026 HealthCare Royalty Partners told a Delaware bankruptcy court that Clearside Biomedical was trying to sell something it did not own. Clearside had filed for Chapter 11 seven weeks earlier with no funded debt and one approved product, the eye drug XIPERE. Its sale papers offered bidders